InterCure and Cookies Successfully Launch Flagship Pharmacy

NEW YORK and TORONTO and HERZLIYA, Israel, June 02, 2022 (GLOBE NEWSWIRE) — InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (“InterCure” or the “Company”) today announced the grand opening of its flagship Cookies Pharmacy in Beersheba, the largest city in the southern region of Israel, known as the capital of the Negev.

The Pharmacy is located in the center of Beersheba opposite the City Hall in a unique building that covers an area of ​​over 1,000 square meters and is completely painted in the world famous Cookies baby blue. To the knowledge of the Company, this is the largest pharmacy in the world dedicated to medical cannabis.

The pharmacy’s premises and staff are uniquely suited to serve Israel’s rapidly growing medical cannabis patient community, which includes, among other things, Israel’s largest pharmacy safe, with a capacity storage of more than one ton of medical cannabis products.

InterCure is marking the occasion with opening festivities throughout the day, which include live music, food trucks, offers and specials for all patients living in Beersheba and surrounding towns. Additionally, for the first time, southern patients will have access to highly demanded GMP Cookies products such as: Cake Mix, Melonatta, Fly and Ooh La La, grown at IntreCure’s southern facility.

“We are pleased to bring our unparalleled quality experience to patients in southern Israel,” said InterCure CEO Alexander Rabinovitch. “Be’er Sheva is the perfect location for the launch of our flagship Cookies Pharmacy, meeting the needs of local patients suffering from a lack of professional service and high quality products. We are proud to invest in the southern capital and to open the largest dedicated medical cannabis pharmacy there with the widest selection of high-quality branded products, meeting patient needs and establishing the infrastructure for the future adult-use market.

“We are incredibly excited to open Cookies in Beersheba with InterCure. InterCure’s best-in-class manufacturing capabilities continue to deliver the highest quality medicines to patients in Israel, and we are excited to continue expanding our global footprint with them,” said Parker Berling, president of Cookies.

About InterCure

InterCure (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) is the leading, profitable and fastest growing cannabis company outside of North America. Canndoc, a wholly owned subsidiary of InterCure, is Israel’s largest licensed cannabis producer and one of the first to offer certified Good Manufacturing Practices (GMP) and pharmaceutical grade medical cannabis products. Cannolam LTD, a subsidiary of the Company, is a pioneer in medical-grade cannabis processing and the retail arm of InterCure, which currently operates 23 pharmacies in Israel. InterCure leverages its market-leading distribution network, best-in-class international partnerships, and a high-margin, vertically integrated “from seed to sale” model to lead the fastest growing global cannabis market in outside of North America.

For more information visit:

About Cookies

Cookies, founded in 2010 by rapper and Billboard-charting entrepreneur Berner and Bay Area breeder and grower Jai, is the world’s most recognized cannabis company. Cookies values ​​the power of the plant and focuses on creating breakthrough genetics. The company offers a collection of over 70 strains of proprietary cannabis cultivars and over 2,000 products. Cookies also actively works to enrich communities disproportionately impacted by the war on drugs through advocacy and social equity initiatives. Based in San Francisco, the company opened its first retail store in 2018 in Los Angeles and has since expanded to over 450 outlets in 17 markets across 54 countries. Cookies was named one of America’s Hottest Brands of 2021 by AdAge; the first cannabis brand to receive this distinction.
Learn more at

Forward-looking statements

This press release may contain forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to InterCure’s goals, plans and strategies, as well as statements, other than statements of historical fact, that address activities, events or developments that ‘InterCure intends, expects, projects, believes or forecasts that it will or may occur in the future, including with respect to the success of the Cookies store launched in Beersheba and its future expansion. These statements are often characterized by terms such as “believes”, “hopes”, “may”, “anticipates”, “should”, “intends”, “plans”, “will”, “expects”. to”, “estimates”, “projects”, “positioned”, “strategy” and similar expressions and are based on assumptions and assessments made in light of experience and management’s perception of historical trends, current conditions, expected future developments and other factors deemed appropriate. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied. many factors could cause the actual operations or results of InterCure to differ materially from the operations and results anticipated in the forward-looking statements, including, but not limited to, following elements: future growth of the Company’s revenues and profitability, planned operations, financial results, business strategy, competitive advantages, strategy for expansion into major world markets, legalization of CBD in Israel and its impacts on the Company, the impact of the COVID-19 pandemic and the war in Ukraine. Forward-looking information is based on a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond InterCure’s control, which could cause actual results and events to differ materially from those disclosed or implied by such information. forward-looking information. These risks and uncertainties include, but are not limited to: changes in general economic, business and political conditions, changes in applicable laws, Israeli, US and Canadian regulatory landscapes and law enforcement related to cannabis , changes in public opinion and perception of the cannabis industry, reliance on the expertise and judgment of senior management, as well as the factors discussed under “Risk Factors” in the Company’s Annual Information Form. company dated April 5, 2022, which is available on SEDAR at, and under the heading “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in the registration statement on Form 20-F, filed with the Securities Exchange Commission on April 28, 2022. InterCure undertakes no obligation to update this forward-looking information, whether as a result of new i information, future events or otherwise, except as expressly required by applicable law.


InterCure Ltd.
Amos Cohen, Chief Financial Officer
[email protected]

A photo accompanying this announcement is available at

Comments are closed.